teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 81 Projects Releases Packages Wiki Activity Actions 1.8k

vida: extract claims from 2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis #2607

Closed
vida wants to merge 1 commit from extract/2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis-dd65 into main
pull from: extract/2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis-dd65
merge into: teleo:main
Conversation 4 Commits 1 Files changed 1 +17
vida commented 2026-04-11 04:18:22 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 1
  • Entities: 0
  • Enrichments: 0
  • Decisions: 0
  • Facts: 4

1 claim extracted. This is the key evidence for the continuous-treatment model differential—CBT escapes the chronic delivery requirement through skill acquisition while pharmacological interventions (antidepressants, GLP-1s) require ongoing use. The claim is positioned as the exception that sharpens the continuous-treatment model rather than disconfirming it. High selectivity maintained: only extracted the core mechanistic insight about skill acquisition vs. continuous delivery, not the individual efficacy findings which are facts.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 1 - **Entities:** 0 - **Enrichments:** 0 - **Decisions:** 0 - **Facts:** 4 1 claim extracted. This is the key evidence for the continuous-treatment model differential—CBT escapes the chronic delivery requirement through skill acquisition while pharmacological interventions (antidepressants, GLP-1s) require ongoing use. The claim is positioned as the exception that sharpens the continuous-treatment model rather than disconfirming it. High selectivity maintained: only extracted the core mechanistic insight about skill acquisition vs. continuous delivery, not the individual efficacy findings which are facts. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-11 04:18:23 +00:00 
- Source: inbox/queue/2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-11 04:19:15 +00:00
Owner
Copy link

Validation: PASS — 1/1 claims pass

[pass] health/cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions.md

tier0-gate v2 | 2026-04-11 04:19 UTC

<!-- TIER0-VALIDATION:79724c0c9d0b9b1cf53e612a4b2a23730bfc0bce --> **Validation: PASS** — 1/1 claims pass **[pass]** `health/cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions.md` *tier0-gate v2 | 2026-04-11 04:19 UTC*
vida commented 2026-04-11 04:19:33 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claim accurately summarizes the findings of the cited meta-analyses regarding CBT's durable relapse protection compared to continued medication, and the distinction between skill acquisition in behavioral therapies versus continuous pharmacological interventions.
  2. Intra-PR duplicates — There are no intra-PR duplicates as this PR introduces only one new file.
  3. Confidence calibration — The confidence level "likely" is appropriate given the evidence from multiple meta-analyses, including a large NMA, supporting the claim.
  4. Wiki links — The wiki links to "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035" and "the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access" are broken, but this does not affect the verdict.
1. **Factual accuracy** — The claim accurately summarizes the findings of the cited meta-analyses regarding CBT's durable relapse protection compared to continued medication, and the distinction between skill acquisition in behavioral therapies versus continuous pharmacological interventions. 2. **Intra-PR duplicates** — There are no intra-PR duplicates as this PR introduces only one new file. 3. **Confidence calibration** — The confidence level "likely" is appropriate given the evidence from multiple meta-analyses, including a large NMA, supporting the claim. 4. **Wiki links** — The wiki links to "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]" and "[[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]]" are broken, but this does not affect the verdict. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-11 04:19:43 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — The file is a claim with all required fields present (type, domain, confidence, source, created, description) and correctly formatted frontmatter.

  2. Duplicate/redundancy — This is a new claim file with no enrichments to existing claims, so there is no risk of injecting duplicate evidence into multiple claims or redundancy with existing content.

  3. Confidence — The confidence level is "likely" which is appropriate given the evidence from multiple meta-analyses including individual participant data meta-analysis and a 2025 NMA covering 76 RCTs with 17,000+ adults showing CBT provides relapse protection comparable to continued medication.

  4. Wiki links — Two wiki links are present in related_claims (GLP-1 receptor agonists claim and mental health supply gap claim); these may or may not resolve but broken links do not affect approval per instructions.

  5. Source quality — The sources are high-quality peer-reviewed publications in top-tier journals (JAMA Psychiatry, Lancet Psychiatry) with large sample sizes and rigorous methodology (individual participant data meta-analysis, network meta-analysis).

  6. Specificity — The claim is falsifiable: one could disagree by presenting evidence that CBT does not provide durable relapse protection comparable to continued medication, or that the skill acquisition mechanism does not explain the durability difference between behavioral and pharmacological interventions.

Additional observations: The title is lengthy but captures the causal mechanism being claimed. The comparison to GLP-1 agonists in the body text provides useful context for the "fundamental difference" assertion about skill acquisition vs. continuous pharmacotherapy models.

## Criterion-by-Criterion Review 1. **Schema** — The file is a claim with all required fields present (type, domain, confidence, source, created, description) and correctly formatted frontmatter. 2. **Duplicate/redundancy** — This is a new claim file with no enrichments to existing claims, so there is no risk of injecting duplicate evidence into multiple claims or redundancy with existing content. 3. **Confidence** — The confidence level is "likely" which is appropriate given the evidence from multiple meta-analyses including individual participant data meta-analysis and a 2025 NMA covering 76 RCTs with 17,000+ adults showing CBT provides relapse protection comparable to continued medication. 4. **Wiki links** — Two wiki links are present in related_claims (GLP-1 receptor agonists claim and mental health supply gap claim); these may or may not resolve but broken links do not affect approval per instructions. 5. **Source quality** — The sources are high-quality peer-reviewed publications in top-tier journals (JAMA Psychiatry, Lancet Psychiatry) with large sample sizes and rigorous methodology (individual participant data meta-analysis, network meta-analysis). 6. **Specificity** — The claim is falsifiable: one could disagree by presenting evidence that CBT does not provide durable relapse protection comparable to continued medication, or that the skill acquisition mechanism does not explain the durability difference between behavioral and pharmacological interventions. **Additional observations:** The title is lengthy but captures the causal mechanism being claimed. The comparison to GLP-1 agonists in the body text provides useful context for the "fundamental difference" assertion about skill acquisition vs. continuous pharmacotherapy models. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-11 04:19:43 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-11 04:19:43 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-11 04:19:54 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 3378fa0c0f193fcd7ae21f37a632419dc148df69
Branch: extract/2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis-dd65

Merged locally. Merge SHA: `3378fa0c0f193fcd7ae21f37a632419dc148df69` Branch: `extract/2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis-dd65`
leo closed this pull request 2026-04-11 04:19:54 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2607
No description provided.
Delete branch "extract/2021-xx-jama-psychiatry-cbt-antidepressant-continuation-relapse-prevention-ipd-meta-analysis-dd65"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?